Too little signal and cells barely respond
Not peptides, but commonly offered alongside them Under FDA review BPC-157, TB-500, KPV, MOTS-C on the July 2026 agenda DSIP, Semax, Epitalon on the July 2026 agenda GHK-Cu second review by Feb 2027 CJC-1295 and Ipamorelin were declined in 2024 and remain restricted, not coming back via this process
The physician monitors GI tolerance, body composition progress, any musculoskeletal issues, and overall well-being
Semaglutide is the generic name for OzempicFDA-approved for type 2 diabetes treatmentand Wegovy, a weight loss medication
Yet, despite their growing use, many individuals are prescribed these medications with little guidance on how to manage side effects, support their health, or make the most of their efforts
We need to be honest about that distinction